by Plus Therapeutics | Oct 1, 2024 | GBM
Plus Therapeutics presented an update on the ongoing ReSPECT-GBM Phase 1/2 clinical trial, evaluating Rhenium (186Re) Obisbemeda for the treatment of recurrent glioblastoma at the 2024 Congress of Neurological Surgeons (CNS) Annual Meeting yesterday. Key...
by Plus Therapeutics | Sep 30, 2024 | Uncategorized
Reminder to come by Plus Therapeutics at the @CNS_update 2024 Annual Meeting at Booth #2038 Plus Therapeutics is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the...
by Plus Therapeutics | Sep 24, 2024 | Uncategorized
Today is #WorldCancerResearchDay! Join us in celebrating the incredible advancements in cancer research and the dedicated researchers working tirelessly to find new treatments and cures. Every breakthrough brings us one step closer to a cancer-free future🔬🌟🎗️ Learn...
by Plus Therapeutics | Sep 23, 2024 | Uncategorized
Cheers to our amazing team members at Plus Therapeutics who are celebrating their work anniversaries this last quarter! Your hard work and dedication make all the difference. Here’s to many more achievements together! 🌟...
by Plus Therapeutics | Sep 20, 2024 | Uncategorized
Don’t forget to come by the Plus Therapeutics booth at these upcoming community events next week in Texas! Our patient advocacy team can’t wait to meet you. 🎗️🧠 https://give.headforthecure.org/event/head-for-the-cure-5k-san-antonio-2024/e544230...
Recent Comments